Market Overview

Sagent Pharma to Launch Flumazenil Injection, USP

Related SGNT
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3
5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years Daily Round Up 1/28/15: FDO, WIA, EFOI, ASPX (Seeking Alpha)

Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6 million. As with all products in Sagent's portfolio, Flumazenil features the Company's PreventIV Measures^SM packaging and labeling, designed to help reduce medication errors.

Posted-In: News FDA


Related Articles (SGNT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional